Patents Examined by Eggerton Campbell
  • Patent number: 6335162
    Abstract: This invention discloses methods, compositions and kits for the detection of extremely low levels of nucleic acid, cells and cellular material in biological samples. The nucleic acid detection systems utilize either the pyrophosphorolysis reaction catalyzed by various polymerases or nuclease digestion coupled with pyrophosphorylation catalyzed by phosphoribosylpyrophosphate synthetase to produce either deoxyribonucleoside triphosphates or ribonucleoside triphosphates. dNTPs are transformed to ATP by the action of nucleoside diphosphate kinase. The ATP produced by these reactions may be detected by luciferase or NADH based detection systems. If more sensitive detection is required, schemes for the amplification of NTPs and dNTPS are provided. A detection system for cells or cellular material in a sample is provided wherein AMP and a high energy phosphate donor added to a sample are converted to ATP by the action of endogenous enzymes, followed by detection of the ATP.
    Type: Grant
    Filed: March 13, 1998
    Date of Patent: January 1, 2002
    Assignee: Promega Corporation
    Inventors: John W. Shultz, Michelle A. Nelson, Donna M. Leippe, Martin K. Lewis, Lisa S. Nelson
  • Patent number: 6331392
    Abstract: The present invention provides methods for screening for bioactive compounds, in particular those that bind to RNA sequences involved in the pathogenesis of disease or in regulation of a physiological function. The methods involve assessing the stability and/or the conformation of an RNA target in the presence and absence of test ligands, and identifying as a ligand any test ligand that causes a measurable change in target RNA stability and/or conformation. In a preferred embodiment, the effect of a ligand on target RNA stability and/or conformation is assessed by measuring the fluorescence polarization of a fluorescently labeled probe.
    Type: Grant
    Filed: March 5, 1998
    Date of Patent: December 18, 2001
    Assignee: Anadys Pharmaceutical, Inc.
    Inventors: Lance G. Laing, Jaime E. Arenas, Sharon T. Cload, James W. Lillie, Andrew A. Pakula
  • Patent number: 6329152
    Abstract: The present invention provides a process for detecting the presence of a target mRNA in an intact cell. The process includes the steps of (a) fixing and permeabilizing with a non- or weakly-crosslinking reagent the cell in the presence of a plurality of oligonucleotide probes, wherein each probe (i) contains about 15 to about 30 nucleotides, (ii) is labeled with a detectable marker, (iii) has a matched Tm of greater than about 60° C., and (iv) specifically hybridizes to a different contiguous region of an open reading frame in the target mRNA with the provisos that each probe does not hybridize to itself, does not hybridize to any other probe and does not hybridize to a contiguous sequence of (A)n9 (C)n9 (G)n or (U)n in the target mRNA where n is an integer greater than 5; (b) removing unhybridized probes from the cell; and (c) measuring the detectable label in the cell.
    Type: Grant
    Filed: November 30, 2000
    Date of Patent: December 11, 2001
    Inventor: Bruce K. Patterson
  • Patent number: 6329198
    Abstract: Human nm23 DNA and protein is disclosed as well as antibodies which recognize human nm23 protein. The DNA and antibodies may be used to detect nm23 in human tumors to predict the malignancy potential of such tumors.
    Type: Grant
    Filed: June 18, 1999
    Date of Patent: December 11, 2001
    Assignee: The United States of America as represented by the Department of Secretary Health & Human Services
    Inventors: Charles Richter King, Patricia Schriver Steeg, Lance A. Liotta
  • Patent number: 6326489
    Abstract: The invention provides an array of surface-bound, bimolecular, double-stranded, nucleic acid molecules, the array comprising a solid support, and a plurality of different double-stranded nucleic acid molecule members, a member comprising a first nucleic acid strand linked to the solid support and a second nucleic acid strand which is substantially complementary to the first strand and complexed to the first strand by Watson-Crick base pairing, wherein at least a portion of the members have a second nucleic acid strand is substantially complementary to and base paired with the first strand along the entire length of the first strand.
    Type: Grant
    Filed: August 5, 1997
    Date of Patent: December 4, 2001
    Assignees: Howard Hughes Medical Institute, President & Fellows of Harvard College
    Inventors: George M. Church, Martha L. Bulyk
  • Patent number: 6322970
    Abstract: A process for determining the identity of a target polypeptide using mass spectroscopy is provided. Depending on the target polypeptide to be identified, a process as disclosed can be used, for example, to diagnose a genetic disease or chromosomal abnormality, a predisposition to a disease or condition, or infection by a pathogenic organism; or for determining identity or heredity. Kits for performing the disclosed processes also are provided.
    Type: Grant
    Filed: September 2, 1998
    Date of Patent: November 27, 2001
    Assignee: Sequenom, Inc.
    Inventors: Daniel Little, Hubert Köster, G. Scott Higgins, David Lough
  • Patent number: 6322988
    Abstract: A method of determining the presence and identity of a variation in a nucleotide sequence between a first polynucleotide and a second polynucleotide comprising, first, providing a sample of the first polynucleotide and selecting a region of the first polynucleotide potentially containing the variation. Then, the selected region is subjected to a template producing amplification reaction to produce a plurality of double stranded polynucleotide templates which include the selected region. Next, a family of labeled, linear polynucleotide fragments is produced from both strands of the template simultaneously by a fragment producing reaction using a set of primers. Then, the location and identity of at least some of the bases in the selected region of the first polynucleotide is determined using the labels present in the fragments.
    Type: Grant
    Filed: December 8, 2000
    Date of Patent: November 27, 2001
    Assignees: BioVentures, Inc., Vanderbilt University
    Inventors: Elliott P. Dawson, John A. Phillips, III
  • Patent number: 6319671
    Abstract: Methods for detecting in a human biological sample the presence of HLA DQB1 alleles 0201/0202, 0302/0303, and/or 0602 which are associated with increased or decreased susceptibility to insulin dependent diabetes mellitus.
    Type: Grant
    Filed: December 13, 2000
    Date of Patent: November 20, 2001
    Assignee: Saigene Corporation
    Inventors: Jack U'ren, Sharon Howard, Vivian H. Gersuk
  • Patent number: 6319672
    Abstract: Method for double-stranded DNA purification, by which a solution containing said DNA in a mixture with other components is passed over a support on which is covalently coupled in oligonucleotide capable of hybridizing with a specific sequence present on said DNA to form a triple helix.
    Type: Grant
    Filed: May 26, 2000
    Date of Patent: November 20, 2001
    Assignee: Aventis Pharma S.A.
    Inventors: Joël Crouzet, Daniel Scherman, Pierre Wils, Françis Blanche, Béatrice Cameron
  • Patent number: 6312913
    Abstract: The present invention provides methods for determining nucleic acid sequences based on known sequences adjacent to the unknown sequences, and reagents for using such methods.
    Type: Grant
    Filed: July 21, 2000
    Date of Patent: November 6, 2001
    Assignee: Incyte Genomics, Inc.
    Inventors: Jonathan T. Wang, Glenn K. Fu, Walter H. Lee, Laura L. Stuve
  • Patent number: 6309821
    Abstract: The present invention provides nucleotide and amino acid sequences for a novel PAC10 human homolog. The present invention also provides for antisense molecules, diagnostic molecules, genetically engineered expression vectors and host cells for the production of purified PAC10 homologs; antibodies, agonists, antagonists and inhibitors of the PAC10 human homolog; and pharmaceutical compositions and methods of treatment based on the polypeptide, its antibodies, ntagonists and inhibitors. The invention further provides diagnostic and theapeutic compositions for the detection and treatment of X-linked congenital abnormalities, such as centronuclear myopathy.
    Type: Grant
    Filed: May 16, 1996
    Date of Patent: October 30, 2001
    Assignee: Incyte Genomics, Inc.
    Inventors: Janice Au-Young, Richard D. Goold
  • Patent number: 6309829
    Abstract: Disclosed is a method for determining the number of repeat units in a repeat region of a target nucleic acid. In a first aspect, the method of the invention includes the steps of annealing a primer to a target nucleic acid; performing a first primer extension reaction using a first primer extension reagent; separating the target-primer hybrid and unreacted first primer extension reagent; performing a second primer extension reaction using a second primer extension reagent, wherein at least one of the first or second primer extension reagents includes an extendible nucleotide having a label attached thereto; separating the target-primer hybrid from unreacted second primer extension reagent; measuring a signal produced by the label; treating the label so as to render the label undetectable; and repeating the above steps until the signal is substantially less than a signal detected in a previous cycle.
    Type: Grant
    Filed: December 3, 1998
    Date of Patent: October 30, 2001
    Assignee: PE Corporation (NY)
    Inventors: Kenneth J. Livak, Adam L. Lowe, Andrew J. Blasband
  • Patent number: 6306585
    Abstract: A gene coding for Pin m III, which is associated with overwintering and frost hardiness in western white pine, has been cloned and characterized. The gene contains an open reading frame of 486 base pairs, encoding a protein of 161 amino acid residues, with a calculated molecular weight of 18002.30 daltons. The predicted isoelectricl point is 5.534. The gene is transcriptionally regulated with the highest expression in fall and winter months. The protein Pin m III is high in infected tissue such as canker. Accordingly, the gene can be used to determine frost hardiness and blister resist fungus susceptibility in conifers.
    Type: Grant
    Filed: October 22, 1997
    Date of Patent: October 23, 2001
    Assignee: Her Majesty the Queen in right of Canada, as represented by the Minister of Natural Resources, Canadian Forest Service
    Inventors: Abul K. M. Ekramoddoullah, Douglas W. Taylor, Xueshu Yu, Santosh Misra
  • Patent number: 6306389
    Abstract: The invention involves the recognition of a previously unidentified protein family which belongs to, the human SCP family. The members of the family, such as SCP-2 and rat SCP-3 homolog are markers for cell transformation. Diagnostic and therapeutic uses of these protein and related molecules are taught.
    Type: Grant
    Filed: June 8, 2000
    Date of Patent: October 23, 2001
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Ozlem Tureci, Ugur Sahin, Michael Pfreundschuh
  • Patent number: 6303322
    Abstract: The present invention is a method for ranking the affinity of each of a multiplicity of different molecules for a target molecule which is capable of denaturing due to a thermal change.
    Type: Grant
    Filed: January 5, 2000
    Date of Patent: October 16, 2001
    Assignee: 3-Dimensional Pharmaceuticals, Inc.
    Inventors: Michael W. Pantoliano, Alexander W. Rhind, Francis R. Salemme
  • Patent number: 6303313
    Abstract: A method of producing libraries of genes encoding antigen-combining molecules or antibodies; a method of producing antigen-combining molecules which does not require an in vivo procedure; a method of obtaining antigen-combining molecules of selected specificity which does not require an in vivo procedure; vectors useful in the present method; and antigen-combining molecules produced by the method. The antigen-combining molecules are useful for the detection, quantitation, purification and neutralization of antigens, as well as for diagnostic, therapeutic and prophylactic purposes.
    Type: Grant
    Filed: November 12, 1999
    Date of Patent: October 16, 2001
    Assignee: Stratagene
    Inventors: Michael H. Wigler, Joseph A. Sorge
  • Patent number: 6303294
    Abstract: There is provided by this invention methods of detecting genetic deletions, translocations, and mutations associated with at least one condition selected from the group consisting of DiGeorge syndrome, Velocardiofacial syndrome, CHARGE association, conotruncal cardiac defect, and cleft palate in a human patient comprising the steps of providing a DNA containing test sample from said human patient; identifying whether there are less than two functional copies of the DiGeorge syndrome critical region loci, whereby said identification of less than two copies of the DiGeorge syndrome critical region loci is indicative of a likelihood that said person has at least one of DiGeorge syndrome, Velocardiofacial syndrome, CHARGE association, conotruncal cardiac defect, and cleft palate. Probes and primers useful in the invention are also provided as are diagnostic kits.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 16, 2001
    Assignees: The Children's Hospital of Philadelphia, The Trustees of the University of Pennsylvania
    Inventors: Beverly S. Emanuel, Marcia L. Budarf, Deborah Driscoll
  • Patent number: 6300068
    Abstract: The present invention relates to the detection of specific nucleic acid sequences after an amplification process, or directly without amplification. In particular, the invention provides for the automation of the amplification and detection process, the amplification and detection of one or more specific nucleic acid sequences, the use of internal controls, reduced potential for contamination caused by the manual manipulation of reagents, and improved reagent compositions to better control assay performance and provide for further protection against contamination.
    Type: Grant
    Filed: February 5, 1999
    Date of Patent: October 9, 2001
    Assignee: bioMerieux Vitek, Inc.
    Inventors: J. Lawrence Burg, Luigi Catanzariti, Bryan W. Kluttz, Geoff A. McKinley, James G. Moe, Marcela Vera-Garcia
  • Patent number: 6297356
    Abstract: The present invention relates to a novel nucleotide sequence encoding a telomeric protein which binds a repeat region of telomeric sequences, and to the protein encoded thereby. Also included within the invention are expression vectors for the production of the telomeric protein and host cells transformed with the nucleotide sequence. In addition, antibodies, probes and antagonists specific for the telomeric protein are contemplated. Methods of identifying antagonists of the telomeric protein, diagnostic methods of identifying the telomeric protein in a sample, and therapeutic uses of the telomeric protein, particularly in the treatment of aging and cancer, are also contemplated.
    Type: Grant
    Filed: February 4, 1998
    Date of Patent: October 2, 2001
    Assignee: The Rockfeller University
    Inventors: Titia DeLange, Dominique Broccoli, Agata Smogorzenska
  • Patent number: 6294325
    Abstract: Isolated nucleic acids which encode a thermostable protein that enhances specific binding of a thermostable mismatch binding protein to bulge loops in a heteroduplex nucleic acid and recombinant vectors comprising nucleic acid which encodes a thermostable protein that enhances specific binding of a thermostable mismatch binding protein to bulge loops in a heteroduplex nucleic acid are disclosed. Also disclosed are isolated thermostable proteins that enhance specific binding of a thermostable mismatch binding protein to bulge loops in a heteroduplex nucleic acid and host cells comprising a recombinant gene which can express a thermostable protein that enhances specific binding of a thermostable mismatch binding protein to bulge loops in a heteroduplex nucleic acid.
    Type: Grant
    Filed: July 5, 1996
    Date of Patent: September 25, 2001
    Assignee: The Mount Sinai School of Medicine of the City University of New York
    Inventor: James G. Wetmur